Consensus: Osteoporosis - Prevention and treatment;Konsensus: Osteoporose - Prävention & therapie

Journal fur Mineralstoffwechsel

Volumn 14, Issue 4, 2007, Pages 185-197

  Bröll, Johann ^a   Resch, Heinrich ^b  

^a Rheuma Ambulatorium Wien Oberlaa   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIANDROGEN; ANTICONVULSIVE AGENT; ANTIRHEUMATIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; FLUORIDE; GLITAZONE DERIVATIVE; GLUCOCORTICOID; GONADORELIN AGONIST; HEPARIN; IBANDRONIC ACID; IMMUNOSUPPRESSIVE AGENT; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

BALNEOTHERAPY; BONE DENSITY; BONE METABOLISM; CONFERENCE PAPER; ESTROGEN THERAPY; HUMAN; HYDROTHERAPY; MINERAL METABOLISM; NUTRITIONAL ASSESSMENT; OSTEOPOROSIS; PATHOGENESIS; PHYSIOTHERAPY; REHABILITATION CARE; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 36749103322     PISSN: 10237763     EISSN: 16809408     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005; 6: 229-38.
2. Bröll H, Resch H, Pietschmann P, et al. Konsensus-Statement: Therapie der postmenopausalen Osteoporose - Anwendungsbereiche von parenteralen Bisphosphonaten. J Miner Stoffwechs 2007; 14: 45-8.
3. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006; 354: 2250-61.
4. Bröll H, Resch H, Dobnig H. Osteoporose. Bedeutung der Knochenqualität. Österreichische Ärztezeitung (Supplementum) Februar 2006.
5. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005; 16: 581-9.
6. Gillespie LD, Gillespie WJ, Robertson MC, et al. Interventions for preventing falls in elderly people. The Cochrane Library 2003; 4.
7. Kannus P, Haapasalo H, Sankelo M, et al. Effect of starting age of physical acitivity on bone mass in the dominant arm of tennis an squash players. Ann Intern Med 1995; 123: 27-31.
8. Bass S, Pearce G, Bradney M, et al. Exercise before puberty may confer residual benefits in bone density in adulthood. J Bone Miner Res 1998; 13: 500-7.
9. Heinonen A, Sievänen H, Kannus P, et al. High-impact exercise and bones of growing girls: A 9-month controlled trial. Osteoporos Int 2000; 11: 1010-7.
10. Andreoli A, Monteleone M, van Loan M, et al. Effects of different sports on bone density and muscle mass in highly trained athletes. Med Sci Sports Exerc 2001; 33: 507-11.
11. MacKelvie KJ, Petit MA, Khan KM, et al. Bone mass and structure are enhanced following a 2-year randomized controlled trial of exercise in prepubertal boys. Bone 2004; 34: 755-64.
12. Das Arznei & Vernunft-Team. Osteoporose. 2. Auflage. Initiative Arznei & Vernunft, Wien, 2005.
13. Taylor RS, Fritzell P, Taylor RJ. Balloon kyphoplasty in the management of vertebral compression fractures: an updated systematic review and meta-analysis. Eur Spine J 2007; 16: 1085-100.
14. Grafe IA, Da Fonseca K, Hillmeier J, et al. Reduction of pain and fracture incidence after kyphoplasty: 1-year outcomes of a prospective controlled trial of patients with primary osteoporosis. Osteoporos Int 2005; 16: 2005-12.
15. Pfeifer M, Begerow B, Minne HW. Effects of a new spinal orthosis on posture, trunk strength, and quality of life in women with postmenopausal osteoporosis: a randomized trial. Am J Phys Med Rehabil 2004; 83: 177-86.
16. Bonner FJ, Sinaki M, Graboris M, et al. Health professional's guide to rehabilitation of the patient with osteoporosis. Osteoporos Int 2003; 14: S1-S22.
17. Bonaluti D, Shea B, Iovine R, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. The Cochrane Library 2002; 3.
18. Pfeifer M, Sinaki M, Geusens P, et al. Musculoskeletal rehabilitation in osteoporosis. J Bone Miner Res 2004; 19: 1208-14.
19. Peterlik M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest 2005; 35: 290-304.
20. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004; 20: 433-9.
21. Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 74: 129-35.
22. Papapoulos SE, Quandt SA, Liberman UA, et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005; 16: 468-74.
23. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with antiresorptive therapy. Bone 2004; 34: 599-604.
24. Cauley JA, Robbins J, Chen Z, et al; Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1729-38.
25. Cummings SR. LIFT study is discontinued. BMJ 2006; 332: 667.
26. Barrett-Connor E, Mosca L, Collins P, et al; Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-37.
27. Cranney A, Guyatt G, Griffith L, et al; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Metaanalyses of therapies for postmenopausal osteoporoses. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570-8.
28. McClung MR, Geusens P, Miller PD, et al; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-40.
29. Bone HG, Hosking D, Devogelaer JP, et al; Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189-99.
30. Black DM, Schwartz AV, Ensrud KE, et al; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927-38.
31. Mellström DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75: 462-8.
32. Chesnut I, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-9.
33. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20: 1315-22.
34. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006; 54: 1838-46.
35. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.
36. Black DM, Greenspan SL, Ensrud KE, et al; PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349: 1207-15.
37. Black DM, Bilezikian JP, Ensrud KE, et al; PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Eng J Med 2005; 353: 555-65.
38. Greenspan SL, Bone HG, Ettinger MP, et al; Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007; 146: 326-39.
39. Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88: 5212-20.
40. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.
41. Gallagher JC, Genant HK, Crans GG, et al. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2005; 90: 1583-7.
42. Chen P, Miller PD, Delmas PD, et al. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006; 21: 1785-90.
43. Dimai HP. Strontium ranelate: a novel concept for the treatment of osteoporosis. Wien Klin Wochenschr 2005; 117: 728-38.
44. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-22.
45. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-68.
46. Reginster JA, Meunier PJ, Roux C, et al. Strontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti fracture efficacy over 5 years in post menopausal osteoporotic women. Abstract OC 31 presented at the ECCEO, 2006, Vienna.